Brookfield Corp’s Sage Therapeutics SAGE Stock Holding History

Brookfield Corp’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-69,549	Closed	-$2.25M	–	752
2022 Q2	$2.25M	Buy	+69,549	New	+$2.33M	0.01%	392

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Brookfield Corp's SAGE Position: Q3 2022 in Review

Brookfield Corp sold out of Sage Therapeutics (SAGE) in Q3 2022, closing a stake of 69,549 shares — an estimated $2.25M sold.

Brookfield Corp first reported a position in SAGE in Q2 2022 and held it in 1 quarter. The position peaked at $2.25M in Q2 2022. 201 funds tracked by Wall St. Rank hold SAGE as of Q3 2022.

Brookfield Corp reported no remaining Sage Therapeutics position as of Q3 2022 after selling out during the quarter.
Brookfield Corp sold 69,549 Sage Therapeutics shares in Q3 2022, an estimated $2.25M.
Brookfield Corp first reported a position in Sage Therapeutics in Q2 2022 and held it in 1 quarter.
Brookfield Corp's Sage Therapeutics position peaked at $2.25M in Q2 2022.
201 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2022.

Based on Brookfield Corp's 13F filing for Q3 2022, filed 14 Nov 2022.